You are here:
In November 2010, the Gavi Board approved a five-year strategy to ensure the Vaccine Alliance delivers on its overall mission from 2011-2015.
Full implementation of the four strategic goals will see Gavi immunise about 250 million children by 2015 and prevent nearly four million future deaths. This includes the roll-out of pneumococcal and rotavirus vaccines to protect against the world's two main child killers, pneumonia and diarrhoea, as well as sustained progress in providing the pentavalent, meningitis and yellow fever vaccines.
Accelerate the uptake and use of underused and new vaccines by strengthening country decision-making and introduction.
Contribute to strengthening the capacity of integrated health systems to deliver immunisation.
Increase the predictability of global financing and improve the sustainability of national financing for immunisation.
Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries.
Gavi's strategy is a roadmap designed to help the Vaccine Alliance respond to changes in the vaccine landscape and set five-year milestones en route to fulfilling its mission. The 2011-2015 strategy, which takes on board lessons learnt from Gavi's first decade, is the latest in three distinct phases of Gavi activity:
This section details the new strategic objectives and operating principles for the current phase (2011-2015) as well as providing an overview of Gavi's initial strategy (2007-2010).
More information is also available on Gavi’s vaccine investment strategy, through which the Vaccine Alliance determines which vaccines are made available to countries through Gavi’s vaccine support programmes. A new strategy is developed every five years when Gavi takes stock of available and expected vaccines and sets new priorities through in depth analysis and widespread consultations. The latest vaccine investment strategy was developed in 2013 for the period 2014-2018.
Over the course of a decade, the weighted average price of pentavalent vaccine (DTP-hepB-Hib) dropped by 43% from US$ 3.56 per dose in 2003 to US$ 2.04 per dose in 2013, with a lowest-ever price of US$ 1.19 from one supplier in 2013.
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2015
modal window here